Psilocybin

Generic Name: Psilocybin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₇N_₂O_₄P

CAS Number: 520-52-5

Unique Ingredient Identifier: 2RV7212BP0

Background: Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With Cancer

Phase 2

Recruiting

Conditions: Cancer
Major Depressive Disorder

Interventions: Drug: Placebo
Drug: Psilocybin

First Posted Date: 2023-07-17

Last Posted Date: 2023-07-17

Lead Sponsor: Sunstone Medical

Target Recruit Count: 56

Registration Number: NCT05947383

Locations: 🇺🇸
Sunstone Medical, PC, Rockville, Maryland, United States

Evaluation of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military Veterans

Phase 2

Not yet recruiting

Conditions: PTSD

Interventions: Drug: Psilocybin

First Posted Date: 2023-05-25

Last Posted Date: 2023-05-25

Lead Sponsor: Combat Stress

Target Recruit Count: 8

Registration Number: NCT05876481

Locations: 🇬🇧
Combat Stress, Leatherhead, Surrey, United Kingdom

The ENHANCE Study: TaVNS and Psilocybin

Phase 1

Recruiting

Conditions: Psychedelic Experiences
Vagus Nerve Stimulation
Healthy

Interventions: Drug: Psilocybin
Device: Transcutaneous auricular Vagus Nerve Stimulation (taVNS)
Behavioral: Psychosocial Support Alone
Other: Sham taVNS

First Posted Date: 2023-05-19

Last Posted Date: 2024-12-06

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 108

Registration Number: NCT05866471

Locations: 🇺🇸
University of Wisconsin - Madison, Madison, Wisconsin, United States

Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer

Phase 1

Completed

Conditions: Metastatic Malignant Solid Neoplasm
Hematopoietic and Lymphatic System Neoplasm

Interventions: Other: Counseling
Drug: Psilocybin
Other: Questionnaire Administration

First Posted Date: 2023-05-08

Last Posted Date: 2024-11-12

Lead Sponsor: University of Washington

Target Recruit Count: 55

Registration Number: NCT05847686

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

Phase 2

Recruiting

Conditions: Major Depressive Disorder

Interventions: Drug: Psilocybin

First Posted Date: 2023-02-17

Last Posted Date: 2024-04-10

Lead Sponsor: COMPASS Pathways

Target Recruit Count: 102

Registration Number: NCT05733546

Locations: 🇺🇸
Clinical Neuroscience Solutions Inc, Jacksonville, Florida, United States
🇺🇸
Kadima Neuropsychiatry Institute, La Jolla, California, United States
🇺🇸
Aims Trial, Plano, Texas, United States

and more 2 locations

Psilocybin in Functional Neurological Disorder

Not Applicable

Not yet recruiting

Conditions: Functional Neurological Disorder

Interventions: Drug: Psilocybin

First Posted Date: 2023-02-10

Last Posted Date: 2023-10-03

Lead Sponsor: King's College London

Target Recruit Count: 24

Registration Number: NCT05723276

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Phase 3

Recruiting

Conditions: Treatment Resistant Depression

Interventions: Drug: Psilocybin

First Posted Date: 2023-02-03

Last Posted Date: 2024-12-02

Lead Sponsor: COMPASS Pathways

Target Recruit Count: 568

Registration Number: NCT05711940

Locations: 🇺🇸
Clinical Innovations, Inc., Bellflower, California, United States
🇺🇸
Catalina Research Institute, LLC, Montclair, California, United States
🇺🇸
CITrials, Riverside, California, United States

and more 64 locations

Neural and Physiological Correlates of Psychedelic Sub-states

Phase 1

Recruiting

Conditions: Neuroimaging
Psychedelic Experiences
Healthy Volunteers

Interventions: Drug: Psilocybin

First Posted Date: 2023-01-26

Last Posted Date: 2023-08-14

Lead Sponsor: Robin Carhart-Harris, PhD, MA

Target Recruit Count: 12

Registration Number: NCT05698511

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Psilocybin for Major Depressive Disorder

Phase 2

Withdrawn

Conditions: Major Depressive Disorder

Interventions: Drug: Psilocybin

First Posted Date: 2023-01-09

Last Posted Date: 2024-07-25

Lead Sponsor: Washington University School of Medicine

Registration Number: NCT05675800

Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)

Phase 2

Active, not recruiting

Conditions: Alcohol Use Disorder

Interventions: Drug: Placebo
Drug: Psilocybin

First Posted Date: 2022-12-12

Last Posted Date: 2024-08-15

Lead Sponsor: Clairvoyant Therapeutics

Target Recruit Count: 128

Registration Number: NCT05646303

Locations: 🇨🇦
MacAnxiety Research Centre, Hamilton, Ontario, Canada
🇨🇦
Department of Psychiatry, Queen's University, Kingston, Ontario, Canada
🇨🇦
Okanagan Clinical Trials, Kelowna, British Columbia, Canada

and more 9 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy